Protara Therapeutics starts Phase 3 trial for IV Choline Chloride in cancer patients.
ByAinvest
Wednesday, Jan 7, 2026 8:05 am ET1min read
TARA--
Protara Therapeutics has initiated its Phase 3 THRIVE-3 clinical trial to evaluate IV Choline Chloride in patients receiving long-term parenteral support. The trial aims to address choline deficiency, which affects 78% of patients on PS and can lead to serious hepatic injury, neuropsychological impairment, muscle damage, and thrombotic abnormalities. IV Choline Chloride has been granted Fast Track designation by the FDA.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet